Incretin analogs (Lily)

N/A

Report date: 2026/04/09 20:00:21
NME

Base Information

Drug NameIncretin analogs (Lily)
Drug Alias NameN/A
ClassificationSmall molecules
Mechanisms of ActionGlucagon-like peptide 1 receptor agonistsGlucose-Dependent Insulinotropic Polypeptide Receptor agonistsGlucagon receptor agonists
TargetsGlucagon-like peptide 1 receptorGlucose-Dependent Insulinotropic Polypeptide ReceptorGlucagon receptor
Therapy Area/IndicationsObesityDyslipidemiasMetabolic Syndrome +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesEli Lilly And Company
China Registration ClassN/A

Develop Information

Active CompaniesEli Lilly And Company
Inactive CompaniesN/A
Active IndicationsObesityDyslipidemiasMetabolic Syndrome +[5] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A